We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Viapath - A New Brand, Same Commitment to Transform Pathology Services
News

Viapath - A New Brand, Same Commitment to Transform Pathology Services

Viapath - A New Brand, Same Commitment to Transform Pathology Services
News

Viapath - A New Brand, Same Commitment to Transform Pathology Services

Read time:
 

On 1 May, 2014, GSTS Pathology and KingsPath unite to become Viapath, a new brand for one of the UK’s leading specialist providers of pathology services. As a public-private partnership, Viapath remains majority owned by the NHS.

With the commercial freedom to invest in growth and innovation, the company is ambitious and committed to the achievement of high clinical standards and high levels of operating efficiency in pathology services across the UK.

Viapath replaces the current brands - GSTS Pathology and KingsPath - at a time when pathology provision in the UK is in a state of great change.

Richard Jones, CEO, Viapath, said: ‘I am proud to lead a team of exceptional people - top scientists, clinicians, laboratory staff and business specialists. We have a clear vision of how our scientific and clinical knowledge translates into a market-leading portfolio of diagnostic tests and services - and a commitment to work in close partnership with hospital and community healthcare providers to improve the lives of patients, every day.’

The origins of the new Viapath organization were set five years ago, when Guy’s and St Thomas’ NHS Foundation Trust formed GSTS Pathology. This was extended late in 2009, when a partnership to provide pathology services to Bedford Hospital NHS Trust was created. In 2010, King’s College Hospital NHS Foundation Trust became an equal partner.

Now, with around 1,000 employees currently processing more than 22 million tests per annum, the work of Viapath touches thousands of lives every day.

The company’s portfolio includes: specialist assays, innovative new approaches to diagnostic pathways, reference services for specific disease states and full facility management.

Advertisement